Competitive intelligence. Solved.

Pharma data for competitive landscapes, due diligence, and AI-powered research.

Findings delivered by email.

Trusted by teams in life science investing, biotech and pharma

  • along with 3 top-30 pharma companies

Today's approach can't answer your billion-dollar questions.

Which drug candidates outperform the standard of care?
Safety and efficacy evidence is scattered across registries, publications and company disclosures.
What is the likelihood that this drug gets approved?
Broad benchmarks can miss the biology, patient population and design of your trial.
How much is this drug worth?
Valuations depend on assumptions about clinical success, timing, pricing and competition.
Which drug programs should we discontinue and which should we keep?
A competitor’s safety readout can change the risk before the next portfolio review.

Your assistant. Gosset’s data.

Keep ChatGPT or Claude.
Add Gosset.

Connect Gosset to the AI you already use. Give it a comprehensive, continuously updated pharma dataset to build on.

ChatGPT / ClaudeWith web search
70%done

A strong first draft.

AI assistants are good at turning the pages they find into a useful starting point.

Coverage
What the search surfaces
Freshness
As current as the pages found
Effort
Search, read, extract, reconcile
Your assistant + Gosset
99%done

Go deeper. Close the gaps.

Ground the report in connected pharma data, pulled directly for your question.

Coverage
Drugs, trials, results, companies & deals
Freshness
A continuously updated dataset
Effort
Query the data. Focus on the analysis.

Illustrative progress.

More complete. More current.

Connected records reveal the assets, trials and relationships a casual search can miss.

Faster to the answer.

Pull the relevant records directly and get to the analysis faster.

Less token overhead.

Less searching and extraction. More of your token budget goes into analysis.

What you can do with Gosset

Competitive Intelligence·Search & Evaluation·Trial Outcome Forecasting·Asset Due Diligence·Portfolio Optimization

Monitor

Competitive Intelligence

  • Safety, efficacy, trial design and biomarker data, connected to the source evidence.
  • Generate comprehensive landscapes for niche and nuanced indications with IP, pricing, and detailed development status.
  • Efficiently understand each drug's market positioning.
  • Get up to speed on the standard of care with reports backed by drug labels and current treatment guidelines.

See exactly what we cover →

Competitive Intelligence

Source

Search & Evaluation

  • Identify drug candidates that outperform the standard of care.
  • Build a shortlist of acquisition candidates from hundreds of pipeline assets.
  • Assess target validation, competitive crowding, and market potential.
  • Search across targets, indications, development stages and deal relationships.

Placebo-adjusted weight loss

Phase 2 trial Phase 3 trial

Efficacy estimands · pp = percentage points.
Separate studies with different populations and durations.

Predict

Trial Outcome Forecasting

  • Calibrated estimates of clinical trial success.
  • Trial completion-date forecasts with a 47-day median improvement over sponsor estimates in our evaluation.
  • Custom models tuned to your company’s historical trials.

How we measure accuracy →

Probability of Trial Success

Gosset model calibration

GossetPerfect calibration

Validate

Asset Due Diligence

  • Bring your proprietary data together with Gosset’s knowledge graph.
  • Target validation informed by competing and discontinued programs.
  • Safety and efficacy benchmarking against competitors.
  • Market sizing informed by pricing data and epidemiology.
  • Patents, regulatory designations and exclusivity timelines.
  • Evidence-based risk analysis.

Development & exclusivity timeline

Illustrative asset scenario

Prioritize

Portfolio Optimization

  • Recommendations based on your pipeline, resources and opportunities.
  • Account for time, cost and likelihood of success across each asset’s remaining trials.
  • Update risk assessments as competing programs develop.

Risk-adjusted NPV

Illustrative portfolio

Asset AAsset B
  • 1M+Trial records
  • 152.7KDrug records
  • 8.8KTargets & classes
  • 193KCompany records
Explore the data →

Security & compliance

Built for enterprise trust

Independently audited and built to the standards your security and legal teams expect.

SOC 2 Type IIIndependently audited security controls
GDPR compliantAligned with EU privacy regulation
Visit our Trust Center →

Backed & supported by

See the evidence behind your next decision.

Get a walkthrough tailored to the questions you're working on.

Request more info

Send a few details and we'll get back to you within one business day.

We'll reply within one business day. No spam, ever.

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call